Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
109 studies found for:    NIAID | Open Studies | HIV/AIDS
Show Display Options
RSS Create an RSS feed from your search for:
NIAID | Open Studies | HIV/AIDS
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
Conditions: Liver Disease;   Steatohepatitis;   HIV
Intervention:
2 Recruiting Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa
Conditions: Latent Tuberculosis;   HIV
Intervention: Device: QGIT
3 Recruiting Reducing Proviral HIV DNA With Interferon-a
Conditions: HIV;   HIV/AIDS
Intervention: Drug: Peg-IFN-α2b
4 Recruiting CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)
Condition: HIV, Inflammation
Interventions: Drug: Assess Safety;   Drug: Effect of drug on viral load;   Drug: Effect of drug on T-cell count;   Drug: Effect of drug on inflammatory biomarkers
5 Recruiting Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
Condition: HIV/AIDS
Intervention:
6 Recruiting Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
Conditions: HIV Infections;   AIDS;   Opportunistic Infections
Intervention:
7 Recruiting Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study
Condition: HIV Infection
Interventions: Drug: Aspirin 81 mg daily;   Drug: Atorvastatin 40 mg daily
8 Recruiting Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
Condition: HIV
Intervention: Biological: Entyvio (Vedolizumab)
9 Recruiting Viral Load in Blood and Lymph Tissues of HIV-Infected Individuals
Condition: HIV Infection
Intervention:
10 Recruiting Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
Condition: Human Immunodeficiency Virus
Intervention:
11 Recruiting Studies of Blood and Reproductive Fluids in HIV-Infected and Non-HIV-Infected Persons
Condition: HIV Infection
Intervention:
12 Recruiting Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
Conditions: Acquired Immune Deficiency Syndrome Virus;   Acquired Immunodeficiency Syndrome Virus;   AIDS Virus;   Human Immunodeficiency Virus;   Human Immunodeficiency Viruses
Intervention:
13 Recruiting Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans
Condition: HIV
Intervention:
14 Recruiting Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Primary and Chronic HIV-Infected Patients
Condition: HIV
Intervention:
15 Recruiting Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
Conditions: Healthy Volunteer;   HIV Vaccine
Interventions: Biological: Ad4-mgag;   Biological: Ad4-EnvC150
16 Recruiting Safety and Virologic Effect of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults
Condition: HIV-1
Intervention: Biological: VRC-HIVMAB080-00-AB (VRC01LS)
17 Recruiting Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
Condition: HIV
Intervention:
18 Not yet recruiting Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
Condition: HIV Infections
Interventions: Drug: Maraviroc;   Drug: Placebo
19 Recruiting Evaluating the Safety and Pharmacokinetics of VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants
Condition: HIV Infections
Intervention: Biological: VRC01
20 Not yet recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.